Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Aficamten in the Chinese Population.
- 1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.
Abstract
Background
Aficamten is a next-generation cardiac myosin inhibitor (CMI) developed for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). Although extensive clinical pharmacology studies have been conducted in Caucasian populations, limited information is available regarding drug-drug interaction (DDI) risks in the Chinese population. Given the contribution of multiple cytochrome P450 (CYP) enzymes to aficamten metabolism and inter-ethnic differences in CYP-mediated metabolic capacity, it is important to characterize DDI risks and associated changes in aficamten exposure in Chinese subjects.Methods
A whole-body physiologically-based pharmacokinetic (PBPK) model of aficamten was developed using clinical data from Caucasian subjects and extrapolated to the Chinese population. The PBPK model was subsequently applied to compare aficamten exposure between Chinese and Caucasian populations and to predict DDIs in Chinese subjects.Results
Ethnic sensitivity analysis indicated that the key PK parameters of aficamten (AUC0-∞, Cmax, and T1/2) were comparable between Caucasian and Chinese populations. Overall, the predicted DDI magnitudes in the Chinese population were generally consistent with the corresponding Caucasian DDI simulations. Specifically, the model predicted that co-administration with the broad-spectrum CYP inhibitors amiodarone and fluconazole increased the AUC0-∞ of aficamten by 1.43- and 2.27-fold, respectively, whereas the strong inducers carbamazepine and rifampicin decreased its exposure by 35% and 71%, respectively. Notably, under the simulated fluconazole or amiodarone co-administration scenarios, the predicted AUC0-∞ of CYP2D6 intermediate metabolizers (IMs) was 2.22-fold and 1.50-fold higher than that in CYP2D6 normal metabolizers (NMs), respectively.Conclusion
The PBPK model predicted substantial changes in aficamten exposure with broad-spectrum CYP inhibitors (eg, amiodarone, fluconazole) and strong CYP inducers (eg, carbamazepine, rifampicin), and identified CYP2D6 IMs receiving fluconazole or amiodarone as potentially sensitive scenarios. These model-based findings provide quantitative information for DDI risk assessment in Chinese subjects but require clinical confirmation.
Related
- Physiologically Based Pharmacokinetic Modeling of Venetoclax in Pediatric Acute Myeloid Leukemia: Food Effects, Age-Related Pharmacokinetics, and Voriconazole-Mediated Drug-Drug Interactions.
- Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity
- Physiologically-based pharmacokinetic model to predict pharmacokinetics of KY0467 in humans and guide dose selection in infants and children
- Population pharmacokinetic modeling of voriconazole based on real-world data for dosing regimen optimization
- Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children
BibTeX
@article{wang2026physiologically,
title = {{Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Aficamten in the Chinese Population.}},
author = {Ziyang Wang and Xiaofei Wu and Ranran Jia and Hongyun Wang},
journal = {Drug design, development and therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s637138},
url = {https://europepmc.org/article/MED/42928782},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Aficamten in the Chinese Population.
AU - Ziyang Wang
AU - Xiaofei Wu
AU - Ranran Jia
AU - Hongyun Wang
PY - 2026
DA - 2026/10/21
JO - Drug design, development and therapy
DO - 10.2147/dddt.s637138
UR - https://europepmc.org/article/MED/42928782
AB - Background Aficamten is a next-generation cardiac myosin inhibitor (CMI) developed for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). Although extensive clinical pharmacology studies have been conducted in Caucasian populations, limited information is available regarding drug-drug interaction (DDI) risks in the Chinese population. Given the contribution of multiple cytochrome P450 (CYP) enzymes to aficamten metabolism and inter-ethnic differences in CYP-mediated metabolic capacity, it is important to characterize DDI risks and associated changes in aficamten exposure in Chinese subjects.Methods A whole-body physiologically-based pharmacokinetic (PBPK) model of aficamten was developed using clinical data from Caucasian subjects and extrapolated to the Chinese population. The PBPK model was subsequently applied to compare aficamten exposure between Chinese and Caucasian populations and to predict DDIs in Chinese subjects.Results Ethnic sensitivity analysis indicated that the key PK parameters of aficamten (AUC0-∞, Cmax, and T1/2) were comparable between Caucasian and Chinese populations. Overall, the predicted DDI magnitudes in the Chinese population were generally consistent with the corresponding Caucasian DDI simulations. Specifically, the model predicted that co-administration with the broad-spectrum CYP inhibitors amiodarone and fluconazole increased the AUC0-∞ of aficamten by 1.43- and 2.27-fold, respectively, whereas the strong inducers carbamazepine and rifampicin decreased its exposure by 35% and 71%, respectively. Notably, under the simulated fluconazole or amiodarone co-administration scenarios, the predicted AUC0-∞ of CYP2D6 intermediate metabolizers (IMs) was 2.22-fold and 1.50-fold higher than that in CYP2D6 normal metabolizers (NMs), respectively.Conclusion The PBPK model predicted substantial changes in aficamten exposure with broad-spectrum CYP inhibitors (eg, amiodarone, fluconazole) and strong CYP inducers (eg, carbamazepine, rifampicin), and identified CYP2D6 IMs receiving fluconazole or amiodarone as potentially sensitive scenarios. These model-based findings provide quantitative information for DDI risk assessment in Chinese subjects but require clinical confirmation.
SN - 1177-8881
ER -